PWAM
TVTX icon

Park West Asset Management’s Travere Therapeutics TVTX Stock Holding History

Park West Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-800,000
Closed -$14.2M – 73
2016
Q2 		$14.2M Buy
800,000
+319,411
+66% +$5.17M 1.44% 26
2016
Q1 		$6.57M Buy
480,589
+130,589
+37% +$1.98M 0.62% 40
2015
Q4 		$6.75M Buy
350,000
+60,322
+21% +$1.21M 0.73% 38
2015
Q3 		$5.87M Sell
289,678
-39,075
-12% -$1.16M 0.54% 50
2015
Q2 		$10.9M Sell
328,753
-158,391
-33% -$4.34M 1.01% 35
2015
Q1 		$11.7M Buy
+487,144
New +$7.43M 1.7% 24

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Park West Asset Management's TVTX Position: Q3 2016 in Review

Park West Asset Management sold out of Travere Therapeutics (TVTX) in Q3 2016, closing a stake of 800,000 shares — an estimated $14.2M sold.

Park West Asset Management first reported a position in TVTX in Q1 2015 and held it in 6 quarters. The position peaked at $14.2M in Q2 2016. 126 funds tracked by Wall St. Rank hold TVTX as of Q3 2016.

  • Park West Asset Management reported no remaining Travere Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Park West Asset Management sold 800,000 Travere Therapeutics shares in Q3 2016, an estimated $14.2M.
  • Park West Asset Management first reported a position in Travere Therapeutics in Q1 2015 and held it in 6 quarters.
  • Park West Asset Management's Travere Therapeutics position peaked at $14.2M in Q2 2016.
  • 126 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2016.

Based on Park West Asset Management's 13F filing for Q3 2016, filed 15 Nov 2016.